Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
QTRX
SELLQuanterix Corporation · Healthcare · United States · $173M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Quanterix Corporation develops and commercializes ultra-sensitive digital immunoassay platforms, Simoa technology, used for detecting and quantifying biomarkers at extremely low concentrations for early disease detection and research. Its proprietary Simoa technology offers significantly higher sensitivity than conventional immunoassays, providing a strong technological advantage in biomarker detection and creating high switching costs. Quanterix is a leader in ultra-sensitive biomarker detection, positioned at the forefront of precision medicine and early diagnostics.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 105.0M | 121.1M | 135.4M | 138.7M | 9.7% | 145.0M | 169.6M | 188.4M | 16.6% |
| EPS | -2.61 | -0.75 | -1.00 | -2.51 | — | -2.37 | -1.23 | -1.36 | — |
| Shares | 37.3M | 38.0M | 38.5M | 46.7M | +25.4% | 47.1M | — | — | — |
| Debt | 44.1M | 41.5M | 37.4M | 37.2M | -5.5% | 35.3M | — | — | — |
| Equity | 357.9M | 350.0M | 330.0M | 295.7M | -6.2% | — | — | — | — |
| Op CF | -48.6M | -18.8M | -35.2M | -77.2M | — | -81.5M | — | — | — |
| Inv CF | -11.1M | -148.5M | -82.3M | 50.2M | — | — | — | — | — |
| Fin CF | 2.3M | 2.7M | 0.5M | -0.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of QTRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| QTRX | Quanterix Corporation(you) | $173M | 20 | SELL |
| RXST | RxSight, Inc. | $215M | 23 | SELL |
| AVH.AX | AVITA Medical, Inc. | $115M | 20 | SELL |
| SGHT | Sight Sciences, Inc. | $267M | 21 | SELL |
| QSI | Quantum-Si incorporated | $168M | 11 | STRONG SELL |
| STIM | Neuronetics, Inc. | $120M | 16 | STRONG SELL |
| TLSI | TriSalus Life Sciences, Inc. | $259M | 16 | STRONG SELL |
| OWLT | Owlet, Inc. | $153M | 11 | STRONG SELL |
| LUCD | Lucid Diagnostics Inc. | $173M | 7 | STRONG SELL |
| LAB | Standard BioTools Inc. | $326M | 22 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%